BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 23189185)

  • 1. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.
    Madsen CB; Petersen C; Lavrsen K; Harndahl M; Buus S; Clausen H; Pedersen AE; Wandall HH
    PLoS One; 2012; 7(11):e50139. PubMed ID: 23189185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.
    Pouniotis DS; Esparon S; Apostolopoulos V; Pietersz GA
    Immunol Cell Biol; 2011 Nov; 89(8):904-13. PubMed ID: 21383765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
    Kissick HT; Sanda MG; Dunn LK; Arredouani MS
    PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour-associated glycan modifications of antigen enhance MGL2 dependent uptake and MHC class I restricted CD8 T cell responses.
    Singh SK; Streng-Ouwehand I; Litjens M; Kalay H; Saeland E; van Kooyk Y
    Int J Cancer; 2011 Mar; 128(6):1371-83. PubMed ID: 20473945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microvesicle cargo of tumor-associated MUC1 to dendritic cells allows cross-presentation and specific carbohydrate processing.
    Rughetti A; Rahimi H; Belleudi F; Napoletano C; Battisti F; Zizzari IG; Antonilli M; Bellati F; Wandall HH; Benedetti Panici P; Burchell JM; Torrisi MR; Nuti M
    Cancer Immunol Res; 2014 Feb; 2(2):177-86. PubMed ID: 24778281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells.
    Hiltbold EM; Alter MD; Ciborowski P; Finn OJ
    Cell Immunol; 1999 Jun; 194(2):143-9. PubMed ID: 10383817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y; Koido S; Ohana M; Liu C; Gong J
    J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes.
    Ninkovic T; Hanisch FG
    J Immunol; 2007 Aug; 179(4):2380-8. PubMed ID: 17675499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice.
    Ryan SO; Vlad AM; Islam K; Gariépy J; Finn OJ
    Biol Chem; 2009 Jul; 390(7):611-8. PubMed ID: 19426130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.
    Stepensky D; Tzehoval E; Vadai E; Eisenbach L
    Clin Exp Immunol; 2006 Jan; 143(1):139-49. PubMed ID: 16367945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1.
    Ding C; Wang L; Marroquin J; Yan J
    Blood; 2008 Oct; 112(7):2817-25. PubMed ID: 18669871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes.
    Ninkovic T; Kinarsky L; Engelmann K; Pisarev V; Sherman S; Finn OJ; Hanisch FG
    Mol Immunol; 2009 Nov; 47(1):131-40. PubMed ID: 19007994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.
    Pathangey LB; McCurry DB; Gendler SJ; Dominguez AL; Gorman JE; Pathangey G; Mihalik LA; Dang Y; Disis ML; Cohen PA
    Oncotarget; 2017 Feb; 8(7):10785-10808. PubMed ID: 27974697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells.
    Gong J; Apostolopoulos V; Chen D; Chen H; Koido S; Gendler SJ; McKenzie IF; Kufe D
    Immunology; 2000 Nov; 101(3):316-24. PubMed ID: 11106934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers.
    Bohnenkamp HR; Coleman J; Burchell JM; Taylor-Papadimitriou J; Noll T
    Cell Immunol; 2004; 231(1-2):112-25. PubMed ID: 15919376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells.
    Vlad AM; Muller S; Cudic M; Paulsen H; Otvos L; Hanisch FG; Finn OJ
    J Exp Med; 2002 Dec; 196(11):1435-46. PubMed ID: 12461079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
    Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
    Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
    Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
    Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognition of pleural mesothelioma by mucin-1(950-958)/human leukocyte antigen A*0201-specific CD8+ T-cells.
    Roulois D; Vignard V; Gueugnon F; Labarrière N; Grégoire M; Fonteneau JF
    Eur Respir J; 2011 Nov; 38(5):1117-26. PubMed ID: 21540305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.